U.S. SENATE: Save the Prostate Cancer Research Program
Now it is time to write your U.S. Senators – TODAY!
A few weeks ago I requested that you write to your member of the House of Representatives, now it is time to write to the other side of congress, the Senate. Write your U.S. Senators today and urge them to support funding for the PCRP by signing the Johnson “Dear Colleague” letter to the Appropriations Committee.
Federal research funding for prostate cancer accounts for around $400 million per year. The Prostate Cancer Research Program at the Department of Defense has received about $80 million per year since 2001. Funding at the PCRP has accelerated the clinical trial process for several drugs over the past couple of years including the recently approved Zytiga (Abiraterone) Additionally, the program has accelerated several other drugs currently in Phase III clinical trials.
In my personal opinion, the PCRP is the most important government funding program for prostate cancer research that exists. PCRP funding also can jump start new innovative research that can be further developed with NIH funds because the program focuses on high-risk, high-reward research that